FOR-OD-26-006
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Not Allowed)
Summary
Commercialization Readiness Pilot (CRP) Program
The Commercialization Readiness Pilot program supports small business concerns in advancing biomedical technologies from late-stage research toward market readiness. Administered across multiple NIH institutes (including NINDS, NCI, NHLBI, NIBIB, and others), the CRP targets innovations in drug development, clinical translation, and biomedical device commercialization. Eligible projects typically involve independent replication of key efficacy studies, Investigational New Drug (IND)-enabling studies, clinical trials, manufacturing scale-up, and regulatory affairs support—activities that bridge the gap between Phase II/IIB SBIR/STTR funding and commercial viability. The program emphasizes translational research spanning computational biology, clinical informatics, and biomedical engineering, with the small business maintaining management oversight while leveraging subcontracted expertise from academic and clinical partners.
-
Who can apply: Small business concerns with a Phase II or IIB SBIR/STTR award active within the last 36 months (or active at requested start date). Critical: CRP applications cannot be submitted until SBIR program reauthorization occurs.
-
Funding & project length: Not stated.
-
Award mechanism: Small Business Innovation Research (SBIR) / Small Business Technology Transfer (STTR) continuation; uses SB1 activity code.
-
Key dates: Notice of Funding Opportunity publication is pending SBIR reauthorization; applications not yet solicited.
-
Best fit for: Small biotech and medical device firms advancing Phase II/IIB innovations through IND-enabling studies, clinical validation, manufacturing optimization, and regulatory pathways.
Insights (6)
Phase II/IIB recency requirement creates narrow 36-month window for applicants
The CRP program explicitly requires applicants to have had a Phase II or IIB SBIR/STTR award active within the last 36 months (or active at the requested start date). This is a hard eligibility gate that eliminates any small business that completed Phase II more than 3 years ago, regardless of project merit or commercialization readiness. Applicants must verify their Phase II/IIB award dates immediately to confirm eligibility before investing in application development.
Program reauthorization contingency creates uncertainty in timeline and actual availability
The NOFO explicitly states that publication and solicitation are contingent on SBIR program reauthorization and extension—applications cannot be submitted until this occurs. This introduces significant uncertainty: the program may not launch, timelines are unpredictable, and applicants cannot rely on this funding source for near-term planning. The notice is advisory only; treat this as a conditional opportunity pending legislative action.
CRP targets late-stage translational work beyond typical Phase II scope
The program explicitly supports IND-enabling studies, clinical trials, manufacturing scale-up, regulatory assistance, and independent replication—activities that Phase II grants typically do not fund. This is a strategic fit for small businesses with Phase II projects that have generated promising preliminary data and are ready to de-risk the path to commercialization. Applicants should assess whether their Phase II work has reached a stage where these later-stage investments would meaningfully accelerate market entry.
SBC must retain management control despite significant subcontracting flexibility
While the program allows substantial subcontracting to academic institutions and other partners (e.g., for clinical trials or regulatory expertise), the SBC is explicitly expected to maintain oversight and management of all R&D. This means applicants must have or develop internal capacity to coordinate complex, multi-partner projects—not simply outsource execution. Weak project management or lack of internal technical leadership will be a competitive liability.
Multi-IC participation across NINDS and 16 other NIH components broadens scope
The CRP spans 17 NIH ICs including NINDS, NHLBI, NCI, NCATS, and others, covering research fields F27, F13, F30, F24, F22 (biomedical technology, drug development, translational research). This breadth suggests the program is not narrowly focused; applicants in neuroscience, cardiovascular, oncology, and other therapeutic areas should all consider fit. However, the specific review criteria and funding priorities for each IC are not yet published, so applicants should monitor the final NOFO for IC-specific guidance.
Pilot program scope and multi-IC structure suggest moderate competition but limited awards
The term 'Commercialization Readiness Pilot' and the contingent nature of the program suggest this is a new, limited initiative rather than a large-scale funding mechanism. The involvement of 17 ICs may distribute awards across therapeutic areas, potentially reducing direct competition within any single field. However, without published funding levels or anticipated number of awards, competitiveness cannot be precisely estimated. Applicants should assume selective funding and prepare highly focused, de-risked proposals.
Key Facts
Deadline
—
Posted
Tue, June 10, 2025
Keywords
Research Areas
Gotchas (3)
CRP program is contingent on SBIR program reauthorization and extension; applications cannot be submitted until this occurs
95%
Source Text
“Publication of this solicitation is contingent upon reauthorization and extension of the SBIR program.”
Applicants must have had a Phase II or IIB SBIR/STTR award active within the last 36 months (or active at requested start date) to be eligible
92%
Source Text
“Recipients with Phase II or IIB SBIR/STTR awards that have been active within the last 36 months, including those that will be active at the requested start date, within the missions of the NIH awarding components identified in this NOFO are encouraged to begin to consider applying for this new NOFO.”
SBC must maintain oversight and management of R&D throughout the award despite significant subcontracting allowed
85%
Source Text
“Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the Small Business Concern (SBC) is expected to maintain oversight and management of the R&D throughout the award.”